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Sepsis is a prevalent, serious medical condition with substantial mortality and a signif-
icant consumption of health-care resources. Its incidence has increased around 9% 
annually in general population over the last years and specially in aged patients group. 
Several risk factors such as comorbidities, preadmission status, malnutrition, frailty, and 
an impared function in the immune system called immunosenescence are involved in 
the higher predisposition to sepsis in the elderly patients. Immunosenescence status 
consists in a functional impairment in both cell-mediated immunity and humoral immune 
responses and increases not only the risk for develop sepsis but also lead to more severe 
presentation of infection and may be is also related with a higher mortality. There is a also 
a concern about to admit patients in the intensive care units taking into account that the 
outcome of elderly patients is poorer compared to younger people. Nevertheless, the 
management of septic elderly patients does not differ substantially from younger people. 
In addition, the quality of life in septic elderly survivors is also lower than in younger 
people. But age, as alone factor, should not be used to determine treatment options 
because the poorer outcomes is thought to be due to the increased comorbidities and 
frailty in this group of patients.
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iNTRODUCTiON
Sepsis is a frequent condition in critically ill patients and is associated with a substantial increase in 
health-care resources consumption. The number of cases of sepsis rose by an average of 9% per year. 
The increase in the incidence of sepsis has been also accompanied by an increase in sepsis-related 
mortality despite actual decreases in mortality rates among hospitalized patients. On the other hand, 
the rapidly increased life expectancy in developed countries makes to understand the different char-
acteristics of severe sepsis in older patients a clinical priority and a challenge for clinicians.
For years, there has been a steady increase in the percentage of people older than 60 years as com-
pared to the total population. In the 1950s, they accounted for only 8% of the population, increasing 
to 10% in 2000, and estimated to reach 21% by 2050 (1). Over the next few decades, the population 
aged over 80 years will double. In 2050, octogenarians will account for 9.6% of the total population 
in Europe and 9% in North America (2). One of the problems arising from population aging is an 
increased incidence and severity of diseases, such as sepsis both in the forms of community-acquired 
and hospital-acquired, as compared to the younger counterparts (3).
Older persons are more prone to infections due to the effects of aging, comorbidities, use of 
invasive devices, and factors associated with institutionalization. It has been shown that around 
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40–50% of all cases of bacteremia occur in older patients (4, 5). 
In addition, the incidence and mortality of severe sepsis in older 
patients has increased progressively to achieve a rate of 26.2 cases 
per 1,000 persons, with a 38.4% mortality rate in patients older 
than 85 years (3).
This increment in the incidence of severe sepsis in aging people 
has been reflected in the demographic changes of bed allocation 
in intensive care units (ICUs), where, at present, older patients 
represent around two-thirds of occupations (6). This situation 
will further increase over the forthcoming years as well as the 
amount of health-care resources required by these patients.
According to the World Health Organization definition, the 
segment of elderly people can be divided into young patients (less 
than 65 years), young elderly (aged 65–85 years), and old elderly 
(over 85 years) (7). It is well known that old elderly patients (over 
or 85  years) is a high-risk population due to their frailty and 
associated morbidity (8).
Moreover, there is a concern about the fate of very old patients 
admitted to the ICU, taking into account that the outcome 
of young elderly and old elderly ICU patients is usually worse 
than that of younger patients independently of the underlying 
diagnosis. Thus, important questions regarding suitability of ICU 
admission, treatment, and quality of life in this group of patients 
still remain unanswered.
In this review, we focus on risk factors, age-related patho-
physiologic mechanisms, and immunologic events that impair 
host antimicrobial defenses in elderly patients with septic shock. 
We also discuss recent findings regarding the clinical impact, 
therapeutic strategies, and prognosis in older patients with sepsis.
RiSK FACTORS
There are several risk factors predisposing elderly patients to an 
increased incidence of sepsis.
Comorbidities and Previous Disorders
Comorbidities and previous disorders as renal and pulmonary 
diseases are usually present in association with an increased 
susceptibility to sepsis, but these comorbidities alone are not suf-
ficient for causing infection, and other factors, such as treatment 
with various drugs or recurrent hospitalizations are necessary to 
compromise immunity in old patients (9).
Preadmission Status
Preadmission status is as important as comorbidities and has 
even been shown to be an independent predictor of outcome 
in the elderly (10). The main alterations in functional status 
include disuse atrophy from an inactive lifestyle, sarcopenia from 
accelerated muscle loss, changes in responsiveness to trophic 
hormones (growth hormones, androgens, and estrogens), neuro-
logical alterations, altered cytokine regulation, changes in protein 
metabolism, and changes in dietary intake (6).
Malnutrition
Malnutrition is also common in the old patient. The fact that 
olfactory discrimination is reduced by age causes an impair in 
different tastes and produces less pleasure for food, contributing 
to the lack of appetite. The nutritional condition of older people 
can be influenced by several factors such as little physical activ-
ity, few resources, motion problems, social isolation, inadequate 
diet, chronic conditions, cognitive impairment, mood disorders, 
teething issues, use of too many medicines, and alcohol or sub-
stance abuse (6, 9).
Drugs
It is necessary to improve our knowledge regarding how aging 
affects the absorption, hepatic metabolism, and response to drugs. 
Pharmacokinetics of drugs is altered in older persons, which may 
result in an increase in potential drug interactions usually due to 
the high number of medications taken, rather than to age (11).
intestinal Microbiota
Gastrointestinal balance is affected by age. Physiologic age-
related changes are due to modification in diet, lifestyle, and 
reduction of functionality of the immune system. Therefore, 
these impairments in intestinal microbiota could be principal 
actors of distinctive conditions of the elderly patient, such as 
frailty, immunosenescence, metabolic syndrome, diabetes, and 
sarcopenia. The gastrointestinal tract contains the most complex 
bacterial ecosystem of the human body and the genome of this 
intestinal microbiota (microbiome) is made up of more than 100 
times the number of genes in the human genome. In summary, 
changes related to age in intestinal microbiota contribute to the 
pathophysiologic processes causing malnutrition, empowering 
inflammatory status, and susceptibility to infection. However, the 
gut microbiota composition of elderly people is still uncertain, so 
we need more studies to complete it, as well as more research of 
new possible treatment strategies such as pro/prebiotics, which 
could be a useful support in individual nutritional strategies to 
improve or preserve elderly population’s health (12).
immunosenescence
The innate immune system is damaged, so it is easier for patho-
gens to access the organism. Indeed, there is enough evidence of 
T- and B-cell dysfunction in aging people.
PATHOPHYSiOLOGY
Aging is unavoidable in humans; it is a polygenic process deter-
mined genetically on the one hand and intimately related to 
exogenous factors influencing each of the individuals throughout 
their life (13, 14). The steady accumulation of somatic mutations 
during an individual’s life results in a decreased capacity of cell 
regeneration, cell repair, and an altered function of the immune 
system.
The immune cells are constantly renewed from the hemat-
opoietic stem cells, and in elderly subjects, both the proliferative 
capacity and the number of these immune cells are decreased 
due to progressive telomere shortening, resulting in an immune 
dysfunction over the years, which is known as immunosenes-
cence (15).
This state of immunosenescence predisposes to the risk for the 
development of sepsis and also causes alterations in the body’s 
response leading to a more severe presentation of infection.
TAbLe 1 | immunosenescence.
Innate immunity 
(15–17, 22, 37, 
43, 46)
Decreased function of macrophages (chemotaxis, 
phagocytosis, apopotosis, TLR expression, and cytokine 
production)
Decreased function of neutrophils (chemotaxis, 
phagocytosis, signal transduction, and apoptosis)
Decreased function in dendritic cells (antigen presentation, 
chemotaxis, and endocytosis)
Decreased in phagocytic capacity
Decreased sensitivity to IFN and growth hormone
Decreased production of TNF-α and IL-6
Increased production of IL-10
Decreased sensitivity to G-CSF
Decreased expression of TLRs
Increased number of NK cells
Decline in NK cell function
Circulating inmature neutrophils
T-cells (17, 19, 20, 
23–25, 40, 43, 
44, 46)
Decreased naïve cells
Decrease naïve CD4 function
Decrease naïve CD8 function
Decreased type 1 cytokine response
Increased type 2 cytokine response
Decreased function of mitogen-activated protein kinases
B-cells (17, 18, 
44, 46)
Decrease in the number of B-cells
Reduced antibody affinity
Decreased response to neoantigens
Increased level of antibodies
Hypogammaglobulinemia
TLR, toll-like receptor; IFN, interferon; TNF, tumor necrosis factor; IL, interleukin; G-CSF, 
granulocyte colony-stimulating factor; NK, natural killer.
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immunosenescence in the elderly
There are functional impairments in both cell-mediated immunity 
and humoral immune responses with age. The thymus, which is 
involved in adaptive cell-mediated immunity, atrophies with age 
and by 60 years causes less activity in the T-cell repertoire from 
naïve T-cells to memory T-cells.
Macrophages present functional alterations, as decreased 
antigen processing and expression to T-cells, reduced bactericidal 
activity and altered expression and function of toll-like receptors. 
Furthermore, others cells involved in innate immunity like neutro-
phils and natural killer (NK) cells are also impaired causing reduced 
recognition and destruction of infected cells (13–24) (Table 1).
Effects of Age on Innate Immunity
The main cells of the innate immune system and the soluble 
mediators (cytokines, hormones, and free radicals) are both well 
preserved in the elderly, even at extreme ages. However, there are 
biochemical and cell function alterations facilitating infection. 
It has been shown that plasma levels of interleukin (IL)-6 and 
IL-1 and tumor necrosis factor (TNF) are elevated in the elderly 
population. This represents a state of constant stimulation of the 
immune system and, therefore, a continuous subclinical inflam-
matory state, which would explain the progression and develop-
ment of many pathologic processes in the elderly (15, 16).
This inflammatory cellular microenvironment also causes 
changes in cell differentiation and behavior of antigen-presenting 
cells. In fact, IL-10, the function of which is to suppress cell-
mediated immunity, is increased in older healthy individuals 
(23–25). Despite these changes in functionality, normal values 
of leukocytes, total lymphocytes, and B- and T-lymphocyte sub-
populations have been reported in observational studies. Many 
differences in cell parameters are found among studies, with the 
largest differences in the CD4/CD8 ratio (26).
A more prolonged proinflammatory response has been gener-
ally observed in elderly patients than in young people. A reduc-
tion in clearance of microbial pathogens could be involved in this 
response. In addition, impairment in the attenuation of signaling 
by counterregulatory cytokines may play a role.
This persistent inflammation could induce an exhaustion of 
T-cells, which may be associated with a reduction in survival in 
the elderly probably due to an increase in the susceptibility to sec-
ondary infections (27). Among innate immune cells, neutrophils 
both in the number of these cells and their precursors in the bone 
marrow are preserved in the elderly (26–32).
By contrast, the number of monocytes and macrophages in 
peripheral blood in elderly subjects are similar to younger peo-
ple, but a significant decrease in macrophage precursors in the 
bone marrow has been found (32). Several studies have shown a 
decreased function of these cells in relation to age. A reduction 
of the phagocytic ability of neutrophils has been observed and 
this low neutrophil response is particularly important in the 
susceptibility to pathogens, such as Staphylococcus aureus, seen 
in older people (15, 29).
In addition, impairment in superoxide generation and an 
increase in the apoptosis in neutrophils from elderly patients 
after antigen stimulation have been observed (33). A reduction of 
intracellular calcium flux and a decline in glycosylation patterns 
of intracellular proteins has been found in activated neutrophils 
from elderly patients (7, 34, 35).
Moreover, it has been observed a reduction in the macrophages 
function with a decrease in the levels of the major histocompat-
ibility complex type II (MHC II) molecules, which results in a 
decreased response of CD4 histocompatibility. Also, there is an 
increase in the synthesis of prostaglandin E2 that stimulates the 
production of cytokines by T-lymphocytes and the long-term 
reconversion of T-lymphocytes type 1 helper into type 2 helper 
(34, 36) (Figure 1).
On the other hand, NK cells also play an important role in 
innate immunity. Impairment in elderly have been observed 
in several studies indicating that the number of NK cells that 
increases with age may be due to a compensatory response to 
a relative loss of the lytic activity (33, 36–40). However, their 
cytotoxic capacity decreases. In fact, it has been observed that 
NK cells have a decreased production and response to interferon 
gamma (IFN-γ) and chemokines after stimulation with IL-2 or 
IL-12 (34, 36, 37).
Effects of Age on the Adaptive Immune System
The adaptive immune system is represented by T- and 
B-lymphocytes. T-lymphocytes mature in the thymus, and this 
process occurs mainly in early childhood until involution of the 
gland by the age of 60. The phenomenon of decreased thymo-
poiesis produces a dramatic reduction of naïve T-lymphocytes 
and although levels remain adequate for years, decreases are 
particularly relevant over 70 years of age (36, 39) (Figure 2).
FiGURe 1 | invading pathogens induce innate immune responses at the infection point. The pathogen agent is taken up by macrophages and dendritic 
cells (DCs). Macrophages present the antigen to the lymph nodes in major histocompatibility complex class II (MHC class II) molecules associated to the secretion of 
proinflammatory cytokines. On the other side, mature DCs migrate to the lymph node and present both MHC class I and II molecules. Infected cells are eliminated 
by natural killer (NK) cells [modified from Ref. (15), with permission of John Wiley and Sons].
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Thymic involution causes a decrease in the production of CD4 
and CD8 lymphocytes leading to a poorer response to neoanti-
gens exposure affecting the adaptive immune system when faced 
to systemic bacterial infections (40).
One of the reasons for the decrease of the adaptive immune 
response observed in older people is caused by the accumula-
tion of effector T-cells with functional alterations resulting in a 
reduction in either cell receptors or IL-2. In addition, an increase 
of memory T-cells leading to an increase in the production of 
cytokines has been reported (33).
In older people, there is a state of chronic inflammation caused 
by an increase of IL-6 and TNF-α levels, resulting in an increased 
sensitivity of CD4 and CD8 cells to induced apoptosis by TNF-α. 
Also, there is an inverted CD4/CD8 ratio, which may be associ-
ated with an increased mortality in these age groups (38, 41, 42).
The CD4/CD8 ratio is used as a marker of both immunose-
nescence and immune activation. It has been also considered a 
mechanism of immune defense and repair. The normal range of 
the CD4/CD8 ratio is between 0.9 and 1.9 in the HIV-negative 
population (43). In elderly patients, most studies have shown an 
increase of CD4/CD8 ratio with age due to CD8 decrease, with 
a normal range between 1.6 and 2.2 (26). Moreover, in nonage-
narian patients, there are differences in comparison to younger 
elderly, with an increase of CD4/CD8 ratio in an important 
percentage of patients (44).
In the humoral immune system, significant changes in rela-
tion to advanced age are also noticed. Plasma B-cells gradually 
decrease; however, elevated levels of circulating immunoglobulins 
especially those derived from polyspecific antibody-producing B 
lymphocyte cells with low affinity for antigens are seen. Many 
of these antibodies react as autoimmune antibodies. Moreover, 
the production of highly specific antibodies produced by 
B-lymphocytes after contact with T-cells is reduced due to lack of 
function of such cells (37).
All these defects contribute to reduce the response of the 
adaptive immune system to pathogens, with an increased risk 
for developing systemic infections, such as sepsis, and also to an 
impaired and reduced vaccine response. In order to investigate 
the effects of aging on humoral immune response, some studies 
have analyzed Ig heavy-chain transcript sequences in both young 
and elderly populations before and after vaccination. Elderly 
patients generally showed a worse and less diversified response 
than younger people that may indicate the negative effect of age 
on the functionality of B-cells (45).
Immunosenescence affects both innate and adaptive immu-
nity, and this is reflected in specific T-cell marks such as an 
inverse CD4/CD8 ratio, loss of naïve T-cells, increased numbers 
of terminally differentiated T-cells, and a reduction in the func-
tion of NK cells, leading to a decreased response to vaccination in 
the elderly. Accordingly, it is important to develop new strategies 
FiGURe 2 | Macrophages and dendritic cells (DCs) activate a clonal expansion of naïve CD4+ and CD8+ T-cell. CD4+ T-cell help and the antigen induce 
the differentiation of naïve B-cells, then into memory B-cells and antibody-secreting cells. Long-term immunity in the blood and lymph nodes is related to T-cells and 
B-cells [modified from Ref. (15), with permission of John Wiley and Sons].
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(new adjuvants, dose and booster adaptation, and immunization 
routes) and protocols to improve vaccine responses, making them 
more effective to prevent infectious diseases and infection-related 
morbidity and mortality (46).
Coagulation
Advanced age is associated with a procoagulable state. Different 
studies have shown an increase in coagulation factors and 
thrombin–antithrombin complexes in healthy older patients as 
compared to healthy younger age subjects. Elevated plasminogen 
activator inhibitor-type I levels has also been observed. This leads 
to an increased risk of thrombosis and decreased clearance of 
circulating fibrin (31, 41).
DiAGNOSiS
The diagnosis of sepsis is challenging and likely to be missed if not 
anticipated. Early signs and symptom may go unnoticed, while 
later clinical presentation can be very severe with very rapid 
progression to septic shock. In fact, the classical manifestations 
of systemic inflammatory response syndrome may be minimally 
present.
In elderly septic patients, febrile response could be blunted in 
up to 47% of cases, but other unusual or non-specific signs, such 
as weakness, malaise, delirium, confusion, loss of appetite, falls, 
or urinary incontinence may be present (41).
In many cases, establishing a prompt and correct diagnosis 
is further complicated by a lack of cooperation in the frail, 
dehydrated, debilitated, and cognitively impaired patient, which 
is a common situation in aging population. It is well known that 
speed in establishing an accurate diagnosis and implementation 
of rapid and effective resuscitation treatment are essential factors 
for optimizing survival rates. However, diagnosing sepsis is not 
always straightforward, particularly in the elderly patient who 
often have complex ongoing disease processes.
The optimal diagnosis of infection and sepsis in all patients 
is based on clinical signs and symptoms. Biologic laboratory 
markers (biomarkers), such as white blood cell count, C-reactive 
protein, procalcitonin, cytokine levels, and (to some extent) 
coagulation markers can potentially be used to assess prognosis 
and development of organ dysfunction, as well as to guide anti-
microbial treatment and evaluation of response.
Recently, new definitions of sepsis aimed to facilitate and 
accelerate the recognition of patients at risk of developing sepsis 
have been proposed. Original concepts of sepsis were focused 
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on inflammation response, but new definitions underline the 
pathobiology mechanisms of the disease. This approach helps 
stratifying patients at risk of sepsis not only for intensivists but 
also for other clinicians who may be less familiarized with this 
type of patients (47).
In this new perspective, sepsis is defined as a life-threatening 
organ dysfunction caused by a dysregulated host response to 
infection. We need to identify infected patients most likely to 
develop sepsis as soon as possible, and sequential organ failure 
assessment (SOFA) is the score most commonly used in the ICU 
setting. An elevated SOFA score is associated with an increased 
risk of mortality. Although this score is not useful for the man-
agement of patients, it is a valuable indicator to characterize 
septic patients. The quick SOFA score based on high respiratory 
rate (≥22  beats/min), low systolic blood pressure (≤100  mm 
Hg), or altered mentation (Glasgow coma scale <15) is useful 
to suspect infection in patients who are at greater risk for a poor 
outcome (47).
In elderly patients, the most common source of sepsis is the 
respiratory tract followed by genitourinary infections, but, in 
general, the sites of infection are similar to patients of other age 
groups, involving the respiratory, urinary, and gastrointestinal 
systems as well as the skin and soft tissues (9, 48, 49).
Also, elderly patients are at increased risk of infections caused 
by multidrug-resistant organisms not only due to immunosenes-
cence but also because of a greater exposure to institutionalization 
and an increased early use of broad-spectrum antibiotics, which 
may select more virulent and resistant strains (48, 49).
Some studies found an increased rate of methicillin-resistant 
S. aureus and vancomycin-resistant Enterococci as causative 
organism of sepsis in older patients. Also, the incidence of 
extended-spectrum β-lactamase producing Klebsiella spp. has 
been found to be higher among patients older than 65 years and 
younger than 14 years (9, 48, 49).
MANAGeMeNT
The “Surviving Sepsis Campaign: International Guidelines for 
Management of Sepsis and Septic Shock” should be followed for 
the general care of elderly patients with severe sepsis and septic 
shock with the same aim of rapid initial management, including 
the 3- and 6-h reanimation bundles, and all measures proposed 
regarding hemodynamic monitoring, mechanical ventilation 
strategies, infection source control, fluid therapy, and nutrition 
(6, 48). On the other hand, a few specific considerations for the 
elderly septic patient should be taken into account.
In the elderly septic patient, it is mandatory to maintain an 
adequate preload in order to increase the cardiac output. However, 
aging patients usually have diastolic dysfunction, so that over-
zealous fluid administration can be problematic. Dobutamine, 
which can be used to improve tissue perfusion could produce 
different effects because of a relative resistance observed in the 
elderly patient and the arrhythmogenic response, in particular, 
in patients with cardiac ischemic disease (9, 48).
In relation to blood transfusion, a hemoglobin target of 7–9 g/
dL, the same than in young adults should be attained. However, 
we should be alert in patients with low central venous oxygen 
saturation and ischemic myocardiopathy, which may be frequent 
in advanced age, because the protocol contradicts the early goal-
directed resuscitation that targets a hematocrit of 30%.
The differences in pharmacokinetic and pharmacodynamic 
parameters such as reduced renal function make us to adjust the 
dosage of antibiotics as well as to consider an increased frequency 
of antimicrobial-related adverse effects in the elderly. In addition, 
older patients may be more susceptible to adverse drug events 
than younger patients (29, 50, 51).
Levosimendan is a calcium-sensitizing drug with inotropic 
and vasodilator properties to treat decompensated heart 
failure (52). Comparing with dobutamine, levosimendan use 
in patients with septic shock has shown improvements in 
hemodynamic variables (microcirculatory flow (53), renal, and 
hepatic function) (54). Results of a meta-analysis support the 
use of levosimendan in patients with sepsis but only 125 patients 
in total had been treated (55). However, data regarding the use 
of levosimendan in the elderly group are scarce. In a recent 
randomized controlled trial, levosimendan as standard therapy 
in a septic shock has not shown any improvement in survival or 
organ dysfunction (56).
The influence of age on the effect of the vasopressor agents has 
been recently examined in the study of Biston et al. (51) showing 
that the doses of vasopressor and adrenergic agents were similar 
independently of age and, therefore, interaction between age and 
vasopressor agents has no significant effect on outcome.
There is controversy with the use of steroids for septic shock, 
despite the fact that adrenal insufficiency is common in patients 
with advanced age.
In the Surviving Sepsis Campaign, due to scarce evidence of 
the lack of effectiveness and serious adverse effects of steroids, 
including hyperglycemia, immunosuppression, and exacerbation 
of myoneuropathy, low dose of intravenous hydrocortisone is 
only recommended in patients in which arterial blood pressure 
cannot be totally restored with fluid resuscitation and vasopressor 
therapy (29, 30, 51).
Furthermore, adequate management of sepsis and septic 
shock in the elderly requires supportive therapy including 
adequate nutrition, ulcer and deep venous thrombosis prophy-
laxis, and ventilatory support when necessary. Recent studies 
have documented that older patients are treated less aggressively 
than their younger counterparts, particularly those >85  years 
old (51).
It has generally been argued that aged patients have a signifi-
cantly shorter life span and that survivors become more depend-
ent and require more social and economical support than other 
age groups (57). However, in the study of Biston et al. (51) of a 
cohort of patients with mixed circulatory shock, old patients who 
survived had a good quality of life a few years after the event.
In the last decades, therapeutic modulation trying to attenu-
ate aberrant immune response during sepsis has been attempted 
without success (58). Based on evidence that pro- and anti-
inflammatory response are mounted simultaneously in septic 
patients (59), new therapeutic strategies have focused to restore 
homeostasis of the immune system and boosting immunity to 
control infection rather than inhibition of the inflammatory 
response (58–60).
TAbLe 2 | immunomodulatory therapies in the septic patient.
Immune 
therapies (59, 
60, 63–70)
Thymosin alpha-1 Recombinant human 
interleukin (IL)-7
Granulocyte colony-stimulating 
factor and granulocity 
macrophage colony-
stimulating factor
Interferon gamma (IFN-γ) Anakinra Exogenous 
immunoglobulins
Possible effect Produces T-cell and 
DC maturation and 
decrease all causes 
of mortality in septic 
patients
Improves lymphocyte 
functionality (CD4 and CD8 
T-lymphocyte proliferations, 
IFN-γ production, or B-cell 
induction)
Increase neutrophil counts 
in blood but limited results in 
sepsis. Improves myelopoeisis 
and granulopoiesis
Restores expression of 
HLA-DR in monocytes 
in all patients. Limited 
the reduction in the LPS. 
Induced tumor necrosis 
factor (TNF)-α response
Blocks 
interleukin-1, 
improving 
survival of 
patients with 
sepsis
Antibacterial effect, 
immunomodulation 
therapy but not 
evidence of benefit 
demonstrated in 
sepsis
Decrease Lymphocyte 
apoptosis
Augments T-cell responses Reduces infection and 
related complications
Increases IFN-γ secretion
Extracorporeal 
blood 
purification 
systems (60–62) 
(no modality 
confers survival 
advantage)
Continuos veno-
venous hemodialysis 
with high cutoff 
dialyzer membranes 
(HCO)
Hemofiltration/conventional 
hemofilter
Hemoperfusion Coupled plasma filtration 
adsorption
Possible effect Effective way to 
eliminate INF-a, IL-B, 
IL-2, and IL-6, IL-10, 
IL-12
Weaker elimination of TNF-α. 
More efficient in removing 
soluble receptor for IL-1 
compared to continuous HD
Restore HLA-Dr expression on 
monocytes. Adsorb activated 
leukocytes and to remove 
circulating cytokines
Remove inflammatory 
mediators
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It is important to underline the greater emphasis made 
on the dysregulated immune response in the last definition of 
sepsis. Two therapeutic approaches are recently proposed for the 
modulation of the aberrant immune response to sepsis (Table 2). 
The extracorporeal blood purification therapies, including 
convection-based strategies such as high-volume hemofiltration, 
high cutoff membrane, hemoperfusion with different adsorbents 
like polymyxin-B or Cytosorb™, and coupled plasma filtra-
tion adsorption could potentially have a positive impact in the 
immune response, despite the effects on removing inflammatory 
and anti-inflammatory cytokines through a modification of the 
phenotype and function of immune cells (61). Nevertheless, the 
efficacy regarding improvement of survival has not yet been 
elucidated and more clinical studies are needed (61, 62).
The second approach is based on reboosting the immune 
system (63). Recent studies have shown that HLA-DR expression 
could be useful in predicting infections and death by identification 
whether or not a patient with sepsis is in the immunosuppressive 
phase of the disease. Investigations in this line take relevance 
when establishing the use of immunomodulatory therapies, 
and it is possible that some patients may benefit from inhibition 
immune system response but, on the other hand, other patients 
could benefit from stimulation of the immune system (58). In 
this context, monocyte HLA-DR expression could be an optimal 
marker to determine the most adequate treatment option (59). In 
this respect, novel therapeutic strategies for severe sepsis and sep-
tic shock are currently considered to try to moderate the damage 
caused by innate immune response in endothelial tissues, and, 
therefore, to prevent secondary infections o reactivation latent 
viruses. The use of thymosin alpha 1 has shown very promising 
results inducing T-cells and dendritic cells maturation and was 
associated with lower mortality in septic patients (64).
Recombinant human IL-7 demonstrated the ability to restore 
normal lymphocyte functions, CD4 and CD8 T-lymphocyte pro-
liferation, IFN-γ production, or induction of B-cells after stimula-
tion (65). It has been reported that the administration of IFN-γ 
to septic patients can restore monocyte HLA-DR expression with 
the result in clearance of sepsis (66). Additionally, it has been also 
demonstrated that IFN-γ partially reversed immunoparalysis by 
attenuating the reduction of TNF-α (67). The use of drugs to 
increase the number of neutrophils has been also investigated but 
with limited results. Clinical trials found no evidence supporting 
the use of granulocyte colony-stimulating factor or granulocity 
macrophage colony-stimulating factor therapy in reducing mor-
tality rate of septic patients (68). Treatment with the IL-1 block-
ing agent anakinra has recently showed good results improving 
survival of patients with organ dysfunction (69).
Therapies with intravenous immunoglobulins have not proven 
effective in sepsis. The differences in the composition, timing 
of administration of immunoglobulin in addition to a lack of 
knowledge of the mechanisms of action could be responsible for 
the different results obtained in the clinical trials (63, 70).
PROGNOSiS AND OUTCOMe
Elderly patients with severe sepsis and septic shock have high 
mortality rates of around 50–60%. The mortality rate due to 
severe sepsis in elderly patients is 1.3–1.5 times higher than in 
younger cohorts. A number of factors independently associated 
with death have been identified in critically ill patients, includ-
ing preinfectious immune or genetic status, nosocomial events, 
comorbidities, severity of illness, age ≥75  years, and impaired 
level of consciousness (51, 71). Hospital mortality rates are also 
higher in frail than in non-frail patients.
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Data regarding subsequent survival and quality of life after 
severe sepsis are limited, especially in the elderly who usually 
have a poorer functional outcome. The long-term prognosis is 
mainly dependent on previous functional status rather than on 
severity of illness at ICU admission (72–75).
It has been suggested that baseline physical function and frailty 
status could aid in prognosis and informed decision-making for 
very old critically ill patients (76). The severity of acute disease on 
admission can also influence in-hospital mortality and mortality 
after discharge in patients aged 80 or over altering greatly physical 
function of long-term hospital survivors (77–80).
It has been shown that elderly ICU survivors has a poorer 
quality of life prior to ICU admission than younger people, and 
although it could improve after hospital discharge, the quality of 
life remains lower than that of the general population (78, 79).
In a Canadian cohort study of 610 patients aged 80  years 
or older who where admitted in the ICU, only 26% of them 
survived and returned to baseline levels of physical function at 
1 year (73). In this study, as lower were age, APACHE II score, 
Charlson comorbidity index, and frailty index, the physical 
recovery was greater. Also, the baseline physical function score 
and the specific diagnoses on admission were associated with 
recovery (73).
Some recent studies observed that advanced age alone is not 
a predictive negative factor for the success of surgical and ICU 
interventions, although associated comorbidities could decrease 
the likelihood of survival at discharge in all age groups (73, 
75–77). It is also known that unplanned admissions to the ICU in 
elderly patients are associated with poorer outcomes as compared 
to planned admissions (71, 78).
It has been estimated that up to 29.6% of very patients were 
refused for ICU treatment, showing a significantly higher sur-
vival in ICU-admitted octogenarians than for patients who were 
considered too ill or old for ICU admission (71–77).
CONCLUSiON
Management of sepsis is a frequent ICU challenge, with sub-
stantial mortality and a significant consumption of health-care 
resources. It is estimated that the number of cases of severe 
sepsis will grow at a rate of 1.5% per year, with a proportional 
increase in the group of patients with advanced age. The increased 
incidence of sepsis in elderly people is associated with a number 
of predisposing factors, including comorbid diseases, preadmis-
sion status, malnutrition, frailty, and an impaired function of 
the immune system (the so-called immunosenescence). The 
immunosenescence status increases both the risk for sepsis and 
a more severe presentation of infection and is probably related 
with a poor outcome.
Different studies have shown that older people have a higher 
mortality in association with severe sepsis, but it is important 
for clinicians to consider separately the general prognosis of a 
population of older patients and the prognosis of the individual 
patient. Age as a single factor predicts the length of stay in the 
ICU, but should not be used either to estimate the outcome or to 
determine treatment options for individual patients, given that 
the increased mortality observed in older patients with severe 
sepsis is thought to be due to the increased comorbidities among 
this group.
Differences in treatment decisions regarding the use of more 
aggressive treatment based only on age without considering other 
prognostic factors could lead an important number of older 
patients to prevent from the benefit from such treatment. On the 
other hand, although survival is the most important outcome, 
the quality of life of survivors is also relevant. New therapeutic 
approaches trying to handle aberrant immune responses like 
immunomodulatory therapies are emerging and may be the 
future in the management of infection, particularly in older 
patients. A better immunologic characterization of the patient is 
a cornerstone to get a better modulatory therapy of the immune 
response.
Elderly population will increase in the forthcoming years, so 
it is a priority for clinicians, especially intensivists, to understand 
the extent of the problem, socially and economically, and to assess 
therapeutic challenges and outcomes from a more efficient and 
effective way.
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